AURINIA PHARMACEUTICALS INC. Aurinia Pharmaceuticals Inc. Share Price
Equities
AUPH
CA05156V1022
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.565 USD | +0.27% |
|
+1.83% | -38.15% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 227M 17.67B | Sales 2025 * | 282M 21.96B | Capitalization | 792M 61.6B |
|---|---|---|---|---|---|
| Net income 2024 * | 9M 700M | Net income 2025 * | 71M 5.52B | EV / Sales 2024 * | 1.75 x |
| Net cash position 2024 * | 395M 30.76B | Net cash position 2025 * | 448M 34.84B | EV / Sales 2025 * | 1.22 x |
| P/E ratio 2024 * |
95.7
x | P/E ratio 2025 * |
11.7
x | Employees | 300 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aurinia Pharmaceuticals Inc.
More recommendations
More press releases
| 1 day | +2.78% | ||
| 1 week | +5.31% | ||
| Current month | +2.40% | ||
| 1 month | +10.56% | ||
| 3 months | +3.35% | ||
| 6 months | -35.54% | ||
| Current year | -38.26% |
1 week
5.22
5.56
1 month
4.995.93
Current year
4.719.43
1 year
4.7112.43
3 years
4.0733.97
5 years
3.5233.97
10 years
1.4133.97
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Martin
FOU | Founder | 52 | 15/06/93 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 28/04/19 |
Robert Foster
FOU | Founder | 65 | 15/06/93 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Foster
FOU | Founder | 65 | 15/06/93 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 25/06/19 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 28/04/19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 0 M€ | 0.00% | - | |
| 0.05% | 0 M€ | 0.00% | - | |
| 0.01% | 9 M€ | -.--% | - | |
| 0.01% | 775 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/06/24 | 5.565 | +0.27% | 396 059 |
| 11/06/24 | 5.55 | +2.78% | 955,171 |
| 10/06/24 | 5.4 | +1.89% | 653,344 |
| 07/06/24 | 5.3 | -1.67% | 761,208 |
| 06/06/24 | 5.39 | -1.28% | 744,331 |
Delayed Quote Nasdaq, June 11, 2024 at 09:00 pm
More quotes
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.55
USD
Average target price
10.14
USD
Spread / Average Target
+82.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.26% | 792M | |
| +18.34% | 124B | |
| +15.06% | 109B | |
| -6.39% | 23.84B | |
| +1.89% | 22.42B | |
| -14.27% | 17.5B | |
| -12.07% | 16.61B | |
| -41.64% | 16.43B | |
| +1.05% | 13.4B | |
| +25.87% | 11.47B |
- Stock Market
- Equities
- AUPH Stock